Abstract: A system and method for securing intellectual property rights in distributed intellectual property. Rights are granted and policed in electronically distributed intellectual property. Use limitations are established by agreement by the content provider and the client. The use limitations are reflected in time-based, usage-based and player based component codes that are used to determine if the client is entitled to use the intellectual property. Intellectual property is protected from unauthorized use by encrypting the intellectual property with a key created from some or all of the component codes. As the component codes are known to both the client and the content provider, no key exchange is required.

Abstract: Disclosed is a test device and a method for qualitatively and/or quantitatively measuring the concentration of an analyte in a biological fluid sample. The test device includes a housing defining a sample port, a test well containing a stirrer and a conjugate, and a test strip disposed within the housing. The test well is also defined by being located between the sample port and the test strip. Fluid flows from the test well onto the test strip, which has a trapping zone which binds the analyte and allows for its detection. A control zone may also be included. The test device is generally adapted to use a sandwich assay. Also disclosed is a system comprising the test device and a signal sensing device; and a method for using the test device.

Abstract: A treatment regimen for rhinitis with rhinorrhea includes a daytime dosage unit containing medication for treating rhinitis and an anticholinergic agent for treating rhinorrhea, and a nighttime dosage unit containing medication for treating rhinitis and an attenuated dosage of anticholinergic agent or no anticholinergic agent.

Abstract: A system and method for securing intellectual property rights in distributed intellectual property. The present invention grants and polices rights in electronically distributed intellectual property. Use limitations are established by agreement by the content provider and the client. The use limitations are reflected in time-based, usage-based and player based component codes that are used to determine if the client is entitled to use the intellectual property. The present invention further protects the intellectual property from unauthorized use by encrypting the intellectual property with a key created from some or all of the component codes. As the component codes are known to both the client and the content provider, no key exchange is required by the present invention.

Abstract: An organizational treatment device and method for the treatment of obstructive pulmonary disease comprising both controller and rescue medications such that the need for rescue medication and consequent need for controller medication can be more certainly determined than at present.

Abstract: A single dosage medication formulation incorporating a beta-adrenergic antagonist and an agent to prevent platelet aggregation to enhance simplicity, convenience, and compliance with the use of these agents.

Abstract: An organizational treatment device and method for the treatment of obstructive pulmonary disease comprising both controller and rescue medications such that the need for rescue medication and consequent need for controller medication can be more certainly determined than at present.

Abstract: A method for treating postprandial hyperglycemia in diabetes mellitus in a human which employs a combination of an aerosolizable topical insulin and a short-acting oral hypoglycemic agent as a regimen taken adjacent to mealtime.

Abstract: Pharmaceutical dosage forms for oral administration of an antihistamine and a decongestant are disclosed. The dosage forms provide an antihistamine in an amount and formulation to exhibit antihistaminic activity in a human for greater than 22 hours; and a decongestant in an amount and formulation to exhibit stimulatory activity in a human for less than 16 hours. The formulation of the invention can be taken once per day to afford symptomatic relief of rhinitis while avoiding stimulation at night.

Abstract: A device and method for use in conjunction with exercise of about one hour or less which enhances convenience, and encourages compliance with a regimen of exercise beverages to accomplish preexercise hydration and postexercise hydration and muscle glycogen replenishment, and which includes a preexercise beverage formulation and a postexercise beverage formulation combined in a unified package with indicia and instructions. The preexercise beverage has a volume of from about 240 ml to about 300 ml, and the postexercise beverage has a volume of from about 300 ml to about 600 ml.

Abstract: A system and method for securing intellectual property rights in distributed intellectual property. The present invention grants and polices rights in electronically distributed intellectual property. Use limitations are established by agreement by the content provider and the client. The use limitations are reflected in time-based, usage-based and player based component codes that are used to determine if the client is entitled to use the intellectual property. The present invention further protects the intellectual property from unauthorized use by encrypting the intellectual property with a key created from some or all of the component codes. As the component codes are known to both the client and the content provider, no key exchange is required by the present invention.

Abstract: A method for treating postprandial hyperglycemia in diabetes mellitus in a human which employs a combination of an aerosolizable topical insulin and a short-acting oral hypoglycemic agent as a regimen taken adjacent to mealtime.

Abstract: A dispensing container which incorporates an aerosolizable topical insulin preparation, at least one oral hypoglycemic agent, and indicia and instructions for their coordinated use as a single therapeutic regimen for the treatment of diabetes mellitus in a human, and a method for treating diabetes mellitus which employs such a device.

Abstract: A single dosage medication formulation has a beta-adrenergic blocker and a cholesterol lowering agent that is a statin combined in a single oral formulation for treatment of and reducing the risk of cardiovascular disease to enhance simplicity, cost reduction, convenience, and patient compliance with the use of these agents.

Abstract: A method and device for organizing, storing, instructing, and coordinating the combined use of topical therapeutic agents, including moisturizing agents, for the treatment of respiratory tract disorders.

Abstract: A sinusitis treatment system having an oral dosage constituent, a topical nasal dosage constituent, indicia and instructions for administration of the oral dosage constituent and the topical nasal dosage constituent as an at least ten-day sinusitis treatment regimen.

Abstract: Pharmaceutical dosage forms for oral administration of an antihistamine and a decongestant are disclosed. The dosage forms provide an antihistamine in an amount and formulation to exhibit antihistaminic activity in a human for greater than 22 hours; and a decongestant in an amount and formulation to exhibit stimulatory activity in a human for less than 16 hours. The formulation of the invention can be taken once per day to afford symptomatic relief of rhinitis while avoiding stimulation at night.

Abstract: A device and method for use in conjunction with exercise of about one hour or less which enhances convenience, and encourages compliance with a regimen of exercise beverages to accomplish preexercise hydration and postexercise hydration and muscle glycogen replenishment, and which includes a preexercise beverage formulation and a postexercise beverage formulation combined in a unified package with indicia and instructions. The preexercise beverage has a carbohydrate concentration of not more than about 9%, and the postexercise beverage has a carbohydrate concentration of at least about 13%.

Abstract: It is perceived that the newer antihistamines, which have been developed so as to be less sedating relative to the "first generation" antihistamines, possess diminished anticholinergic effects on rhinorrhea, compared to first-generation antihistamines. It is also perceived that no oral medicinal formulation is presently available for treatment of allergic rhinitis that provides both antihistaminic and anticholinergic actions and is unlikely to produce sedation. This invention provides such a formulation.

Abstract: An integrated package including two nutrient beverage formulations in discrete, sealed containers and instructions for use of the formulations in conjunction with a relatively short exercise session to enhance performance and reduce the adverse effects of the exercise. The formulations are compatibly designed for the needs of the different phases of exercise. The formulations are provided in either fully-constituted liquid form or as water-soluble concentrates. The formulations are combined in a unified package with indicia and instructions. The formulations include fluids, electrolytes, carbohydrates, and other optional agents including vitamin E, glycerol, alkaline salts, stimulants, creatine, specific amino acids, aspartates, phosphates, and pyruvate.